TKS1225
Thiakis' lead compound for the treatment of obesity is TKS1225, a potent long acting analogue of oxyntomodulin currently in Phase I clinical development. Preclinical models have demonstrated TKS1225 to be highly efficacious with respect to the reduction of food intake and body weight, ameliorating glucose intolerance, and leading to improvements in related plasma markers of obesity.

Phase I clinical studies were initiated in March 2008.

About oxyntomodulin
Oxyntomodulin is a gut peptide involved in energy homeostasis in man. Released following food ingestion, it acts as a natural satiety signal to regulate energy intake, and increase energy expenditure.

Previous research has provided proof of concept for oxyntomodulin as an obesity target. A four week placebo-controlled double-blind trial in which healthy overweight volunteers self-administered oxyntomodulin subcutaneously three times daily, led to a reduction in body weight of 2.3 kg in comparison to 0.5 kg in the control group.

A single intravenous infusion of oxyntomodulin to human volunteers in a cross-over study reduced ad libitum food intake at a buffet meal by 19% compared with a saline control, In a further study oxyntomodulin increased activity-related energy expenditure by 26% (increasing total energy expenditure by 9%).